Introduction
By virtue of its central role as a general transcription factor, the c-Myc oncoprotein regulates a number of key normal cellular processes such as growth, proliferation, cell cycle progression, apoptosis and differentiation (Grandori et al., 2000; Adhikary and Eilers, 2005; Meyer et al., 2006) . The importance of c-Myc is underscored by the fact that its inhibition leads to cell cycle arrest in vitro and early embryonic lethality in vivo (Prochownik et al., 1988; Trumpp et al., 2001; Zhou and Hurlin, 2001; Lutz et al., 2002) . Furthermore, deregulated overexpression of c-Myc, either in vitro or in vivo, leads to malignant transformation (Grandori et al., 2000; Lutz et al., 2002) . Taken together, these data suggest that the accumulation of c-Myc mRNA and protein in numerous and diverse human tumors plays a role in the pathogenesis of these neoplasms (Nesbit et al., 1999) .
The critical importance of c-Myc as a transforming oncogene has led to a number of strategies designed to inhibit its expression or function (Prochownik, 2004; Ponzielli et al., 2005; Vita and Henriksson, 2006) . These efforts have been fueled, in part, by experimental systems showing that tumor cell proliferation and/or survival rely upon sustained expression of c-Myc (Adhikary and Eilers, 2005) . Despite these findings, the idea that all cells have an obligate requirement for c-Myc has recently been challenged. For example, somatic knockout of both alleles of c-myc in spontaneously immortalized rat fibroblasts resulted in a several-fold reduction of proliferation but not in its complete inhibition (Mateyak et al., 1997) . In liver, the conditional inactivation of c-myc impairs hepatocyte proliferation in neonatal but not adult mice (Baena et al., 2005) , although another report suggested that proliferation of adult hepatocytes is also c-mycindependent . Accordingly, conditional inactivation c-myc did not affect self-renewal of intestinal mucosa in juvenile and adult mice (Bettess et al., 2005) . Additionally, c-myc was found to be dispensable for proliferation of mouse skin keratinocytes in vivo, but not for their transformation by activated H-Ras . Based on these results, it is conceivable that the proliferation of certain types of cells occurs via c-Mycindependent pathways. In accord with this suggestion, we and others have demonstrated that resumption of normal proliferation as well as other aspects of c-Myc phenotype can be imparted to c-myc knockout fibroblasts by overexpression of individual downstream c-Myc target genes (Hermeking et al., 2000; Nikiforov et al., 2002; Rothermund et al., 2005) . Together, these results raise the formal possibility that, due to their genetic heterogeneity, some tumor cells may overcome their dependency on c-Myc by expressing the proper combination of surrogate genes. Clearly, determining the extent to which this is true is critical before serious consideration can be given to the use of c-Myc inhibitors in the clinical setting.
In normal cells, inhibition of c-Myc invariably results in a G 0 /G 1 cell cycle arrest (Prochownik et al., 1988; Mateyak et al., 1997; de Alboran et al., 2001; Prathapam et al., 2006) . The type of cell cycle arrest caused by c-Myc depletion in tumor cells has not been adequately studied. Data available to date on this subject were collected on small number of lines (Skorski et al., 1995; McGuffie et al., 2000; Chen et al., 2001; Hermeking, 2003) and the methods utilized for inhibiting c-Myc were not consistent (D'Agnano et al., 2001; Citro, 1998) . Therefore, the extent to which tumor cells resemble normal cells with regard to the type of cell cycle arrest, if any, caused by c-Myc depletion remains unclear.
In the current report, we have for the first time undertaken a comprehensive study of the phenotypes caused by c-Myc depletion in a large number of human tumor cell lines (22) and in three reference normal human cell types (fibroblasts, keratinocytes and melanocytes). For this purpose, we utilized a standardized and specific method of reducing endogenous c-Myc levels, for example, lentivirus-mediated delivery of short hairpin c-Myc RNAs (Myc-shRNAs). This approach was able to provide stable inhibition of c-Myc in nearly 100% of cells. As a result of these studies, we have demonstrated that the requirement for c-Myc to maintain proliferation is absolute in all examined cells, suggesting that this could be generally true. However, unlike normal cells, which invariably arrest in G 0 /G 1 phase of the cell cycle in response to c-Myc depletion, tumor cells exhibit significant heterogeneity with regard to the positioning of cell cycle arrest. As demonstrated here, this heterogeneity could be dependent upon the intactness and relative importance of other cell cycle control pathways.
Results

Selection of human c-Myc-specific shRNA
To determine whether tumor cell proliferation depends on c-Myc, we depleted its endogenous levels using lentivirus-delivered shRNAs. As a prelude, several candidate Myc-shRNAs were cloned into lentiviral vector H1, which also encoded enhanced green fluorescent protein (eGFP) (Ivanova et al., 2006) . In addition, a set of commercially available human c-Myc-specific shRNAs in the pLKO1 vector was also tested. The specificity and effectiveness of these shRNAs were first tested in immortalized c-myc-null rat fibroblasts (HO15.19) (Mateyak et al., 1997) reconstituted with human c-Myc cDNA (HO15.19-h-c-Myc). The 'mycnull' phenotype has been extensively characterized in HO15.19 cells, and therefore these cells serve as an excellent reference line in which to study shRNAmediated inhibition of c-Myc expression. Supplementary Figure S1 Inhibition of proliferation of normal and tumor cells by Myc-shRNAs We studied 22 human tumor cell lines originating from a wide variety of adult and pediatric cancers (Table 1) . Normal control cells consisted of primary human foreskin keratinocytes, melanocytes and fibroblasts. All cells were infected with control shRNA or Myc-shRNAs as described in Materials and methods. The efficiency of infection was quantified by counting GFP-positive cells (which was always X95%, not shown). When possible, the degree of c-Myc inhibition was monitored within 48-96 h after infection by western blotting (Figure 1a , Supplementary Figure S2 and data not shown). Our analysis revealed that Myc-suppressing activities of M1, M2 and M3 varied significantly among different lines (data not shown). Therefore, based on preliminary experiments, we utilized Myc-shRNAs, which provided the most efficient inhibition of c-Myc in a given cell line.
In order to evaluate the impact of Myc-shRNAs expression on cell proliferation, cells were plated at low density 2 days after infection and were counted and/or photographed during the ensuing 6 days. As seen in Figure 1b and Supplementary Figure S3 , all cells c No apparent changes in the cell cycle parameters.
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infected with control lentiviral continued to proliferate logarithmically. In contrast, cells infected with the MycshRNAs showed an abrupt cessation of proliferation starting at day 3 or 4 post infection. In some cases, cells underwent apoptotic death starting as early as day 4 post infection (Supplementary Figure S4) .
In several cases, we observed the eventual emergence of proliferating cells from Myc-shRNA-infected cultures. Western blot analysis revealed that c-Myc expression, while initially low, had returned to the pre-infection levels of control cells (not shown). This suggested that these cells had somehow escaped Myc-shRNAs action or that the efficiency of infection of these cells was suboptimal, thus allowing for the outgrowth of cells with a proliferative advantage. We therefore conclude that the continuous suppression of c-Myc is mandatory for the proliferative arrest of all cell lines examined.
Cell line-specific effects of c-Myc depletion A large body of literature suggests that inhibition of c-Myc in primary cells or non-transformed cell lines generally leads to a strong proliferative arrest in the G 0 / G 1 or G 1 /S phases of the cell cycle (Prochownik et al., 1988; Mateyak et al., 1997; de Alboran et al., 2001; Prathapam et al., 2006) . In order to determine whether this is also the case for tumor cells, we used propidium iodide (PI) staining and flow cytometry to evaluate the cell cycle parameters of the above-described cells 4-5 days after infection ( Figure S3B) , we conclude that c-Myc depletion blocks cell cycle progression in these cells equally in all phases. The cell cycle profiles of all other cancer lines were basically similar to one of those described above (Table 1 , Supplementary Figure S5 ). Independent infection of a number of these lines with another c-Myc-shRNA lentivirus produced similar results thus indicating that the cell cycle arrest was truly a specific consequence of c-Myc depletion (not shown).
Our findings indicate that the cell cycle response to c-Myc depletion in normal cells is invariably associated with G 0 /G 1 arrest. However, among tumor cell lines, considerable cell cycle heterogeneity is observed, even among lines derived from identical tumor types. These observations suggest that other factors, whose expression levels or mutational status differ between normal and tumor cells, determine the type of cell cycle arrest in c-Myc-depleted tumor cells.
Inhibition of p53 or p21 alters the cell cycle profile of c-Myc-depleted cells We were interested in understanding the molecular mechanisms that allow cells from several tumor lines to escape the G 0 /G 1 growth arrest that characterizes c-Mycdepleted normal cells. It is well accepted that the expression of factors promoting G 0 /G 1 arrest in response to different forms of stress can be altered in tumor cells (Hahn and Weinberg, 2002) . Therefore, we hypothesized that qualitative or quantitative differences in such factors might underlie the different cell cycle profiles of c-Myc-depleted normal and tumor cells. To test this hypothesis, we first investigated the impact of inhibiting the p53 tumor suppressor protein on the cell cycle parameters of c-Mycdepleted cells undergoing G 0 /G 1 arrest. We focused on p53, since it is involved in the G 1 /S checkpoint and because its inactivation or loss occurs frequently in tumor cells (Hanahan and Weinberg, 2000) . To this end, we chose melanoma lines SK-Mel-19, -29, -103 and -147, which express wild-type p53 (Soengas et al., 2001) , and which arrest in G 0 /G 1 in response to c-Myc depletion (Figure 2 ). Primary melanocytes were also included in the experiment to compare cell cycle responses between normal and tumor cells of similar origin. As shown in Supplementary Figure  S6 , depletion of c-Myc resulted in slight increase in p53 levels in SK-Mel-19 and SK-Mel-29 cells and in moderate increase in p53 levels in SK-Mel-103 and SK-Mel-147 cells: 1.5-2 fold and 2.4-3.3 fold, respectively. Simultaneous suppression of p53 and c-Myc (by M1 shRNA) (Figure 3a ) led to differences in the cell cycle arrest profiles among the studied cells (Figure 4) . In normal melanocytes and cells from lines SK-Mel-19 and SK-Mel-29, G 0 /G 1 phase was increased by 17, 30 and 32%, respectively, in response to c-Myc depletion only and by 25, 49 and 50%, respectively in cells depleted of both c-Myc and p53 (Figure 4) . Depletion of c-Myc alone in melanoma cells SK-Mel-103 and SK-Mel-147 also resulted in corresponding increases of G 0 /G 1 phase by 17 and 21%. In contrast, concurrent c-Myc and p53 depletion in these cells, rather than increasing the G 0 /G 1 population actually caused modest declines of 17 and 11%, respectively and concomitant increases in the G 2 /M populations by 85 and 92%, respectively (Figures 3a and 4) . Similar results were obtained with M2 shRNA (shown for SK-Mel-103 cells in Supplementary Figure S7 ). These data suggest that p53 levels could indeed influence the cell cycle consequences of c-Myc depletion in at least some tumor cell lines. Of note was that all c-Myc-depleted cells, irrespective of their p53 levels and wherein the cell cycle arrest occurred, showed total inhibition of proliferation (Figure 3b ). This suggested that suppression of p53 is not sufficient to rescue the proliferative deficiencies caused by c-Myc depletion.
One of the major mediators of p53-directed cell cycle arrest is the cyclin-dependent kinase inhibitor (CDKI) p21 CIP/WAF (El-Deiry et al., 1993) . We therefore assessed its role in mediating G 0 /G 1 growth arrest induced by c-Myc depletion. As shown in Figures 3 and 4 , inhibition of p21 CIP/WAF in all cell lines resulted in patterns of cell cycle arrest similar to, although less pronounced than those observed in p53-depleted cells.
Taken together, our data suggest that c-Myc is essential for proliferation of all tested normal and tumor cells. However, the rate-limiting function of c-Myc in controlling cell cycle progression is cell linedependent and is variably reliant upon the status of other cell cycle checkpoint regulators, even within tumors originating from the same cell type. CIP/WAF -shRNAs as described in Materials and methods. Two days later, cells were superinfected with control or Myc shRNA (M1) lentiviral vectors. Cells were collected for cell cycle analysis 4 days after the second infection.
Discussion
The widespread deregulation of c-Myc in many tumor types together with its role in maintaining the transformed state in certain experimental settings (Arvanitis and Felsher, 2006) has provided the rationale for its consideration as a prime therapeutic target. Indeed, a number of novel strategies have already been employed to inhibit c-Myc expression or function in tumor cells (Hermeking, 2003; Prochownik, 2004; Ponzielli et al., 2005) . In several transgenic mouse models of c-Mycmediated tumorigenesis, abolishing c-Myc overexpression has been shown to lead to complete tumor regression (Felsher and Bishop, 1999; Pelengaris et al., 1999 Pelengaris et al., , 2002 Jain et al., 2002) . In contrast to these reports, c-Myc appears to be dispensable for the maintenance of mouse mammary gland tumors (Boxer et al., 2004) . It is also noteworthy that in all the above mouse models, c-myc was an initiating oncogene leading to transformation, whereas this is unlikely to be the case with the majority of spontaneously arising human cancers. Therefore, the absolute requirement of c-Myc for proliferation of tumor cells in general and human tumor cells in particular still remains an open question.
The studies reported here, performed with a variety of human tumor cell lines, indicate that they are all highly susceptible to Myc-shRNA-mediated growth inhibition. Indeed, some cell lines demonstrated marked growth arrest even when c-Myc ablation was less than complete (70-80% inhibition), thereby suggesting that human cancers could be sensitive to anti-c-Myc therapies that only partially reduce c-Myc levels or function. On the other hand, it was reported that loss of c-Myc did not inhibit proliferation of normal mouse hepatocytes (Baena et al., 2005; Li et al., 2006) , keratinocytes and intestinal epithelium (Bettess et al., 2005) in vivo. There are several possible explanations for the difference between our data and those of Baena et al. (2005) ; Oskarsson et al. (2006) and Li et al. (2006) . The first one is that in some cases proliferation of c-Myc-depleted cells could continue to depend on the expression of other Myc family members, including N-Myc, which has been shown to functionally compliment c-Myc in in vivo settings (Malynn et al., 2000) . The second explanation is that expression of c-Myc downstream targets that are critical for the proliferation of the above cells in mouse could depend on the presence of cytokines or hormones (such as, for example, hedgehog protein for skin development (Athar et al., 2006) that are absent in the media routinely used in tissue culture. Finally, it is possible that proliferation of human tumor cells is more dependent on c-Myc than that of normal mouse cells, a phenomenon known as oncogene 'addiction' (Sharma et al., 2006) .
The requirement of c-Myc for normal cell cycle progression has been extensively studied in primary or immortalized rodent cells where c-Myc inactivation results in severe or complete inhibition of proliferation and growth arrest predominantly in G 0 /G 1 (Prochownik et al., 1988; Mateyak et al., 1997; de Alboran et al., 2001; Prathapam et al., 2006) . Our data obtained in three different types of primary human cells are in good agreement with the majority of the above reports. On the other hand, while also achieving complete proliferative arrest in tumor cells following c-Myc depletion, we observed considerable variability in cell cycle consequences.
Tumor progression is often accompanied by mutations affecting genes whose products control G 1 /S transition (Hanahan and Weinberg, 2000) . Therefore, the mechanisms involved in implementing G 0 /G 1 growth arrest in response to c-Myc depletion present in normal cells could be impaired in tumor cells. Depending on the nature of these defects, c-Myc depletion would affect G 1 /S transition differently, even in tumors of the same type as shown in the current work. Consequently, due to the involvement of c-Myc in multiple cellular processes (Eisenman, 2001; Patel et al., 2004) , its inhibition may result in activation of other cell cycle checkpoints downstream to G 1 /S, including those involving S (Gottifredi and Prives (2005) or G 2 /M (Stark and Taylor, 2006) .
We demonstrated that interference with levels of p53 and its downstream CDKI target p21 WAF/CIP in two melanoma lines Figure S6 ). Interestingly, an observed increase in p53 levels (at least in SK-Mel-103 and SK-Mel-147 cells) is unlikely to be dependent on p14 ARF since this gene is deleted in both of these cell lines (Paz et al., 2003) . The simplest explanation for the difference in p53 or p21 CIP/WAF dependency of G 0 /G 1 -growth arrest induced by c-Myc-depletion in studied cells is that, in addition to p53 and p21 It is conceivable that G 0 /G 1 arrest caused by c-Myc inhibition could occur via at least two non-mutually exclusive mechanisms. The first could involve deregulated expression of c-Myc-dependent checkpoint genes (CDKs and CDKIs, such as cdk4 and p27
KIP1
; Bernard and Eilers, 2006; Dang et al., 2006) . Alternatively, c-Myc inactivation could lead to changes in the pools of specific cellular metabolites, since c-Myc directly regulates genes whose products play key roles in several metabolic pathways (Dang, 1999) . The consequences of these alterations could be growth arrest at different stages of the cell cycle depending on the status of other key cell cycle regulators. In accord with the latter suggestion are the findings that depletion of the pyrimidine nucleotide pool in normal fibroblasts, achieved by chemical inhibition of the direct c-Myc target CAD (Carbamoyl-phosphate synthetase 2, Aspartate transcarbamylase, Dihydroorotase), results in G 0 /G 1 growth arrest. Interestingly, similar inhibition of CAD in p53-null fibroblasts also results in growth arrest, although in S-phase rather than G 0 /G 1 (Agarwal et al., 1998) .
In conclusion, our findings regarding the absolute reliance of tumor cells on endogenous levels of c-Myc could be important when considering therapeutic approaches that aim to target this oncoprotein. The considerable differences in the cell cycle responses to c-Myc depletion noted here also point to yet additional heterogeneity at the level of other cell cycle regulators, even within tumors arising from the same tissues.
Materials and methods
Tumor cell lines
A list of the tumor cell lines used is provided in Table 1 . Cell lines were originally obtained from the ATCC or from Memorial Sloan Kettering Cancer Center. Cells were cultured in either RPMI-1640 or Dulbecco's modified Eagle's essential minimal medium as recommended by the supplier. Supplements included fetal calf serum (10-20%), 2 mM glutamine and 100 U ml À1 penicillin G þ 100 mg ml À1 streptomycin. All cell culture agents were purchased from Invitrogen Inc. (Carlsbad, CA, USA). Primary fibroblasts, melanocytes and keratinocytes were obtained from neonatal foreskin and maintained as described before (Fernandez et al., 2005; Denoyelle et al., 2006) .
Plasmids and transfections
The lentiviral vector containing shRNA specific for p53 was described before (Boiko et al., 2006) . The lentiviral vectors containing an shRNA specific for human p21 CIP/WAF and for human c-Myc were purchased from Sigma. The lentiviral construct H1 (Ivanova et al., 2006) was used to express shRNAs directed against human c-Myc. The c-Myc targeting sequences consisted of nt. 1567-1585 (M1), 1341-1359 (M2) and 1919-1937 (M3) of the previously published sequence (GenBank Accession no. NM_002467.3). A control lentiviral vector contained an irrelevant sequence. Lentiviral packaging reactions were performed in the 293-FT cell line in the presence of packaging plasmids pVSV-G and pDDR (Ivanova et al., 2006) using Superfect Transfection Reagent (Qiagen Inc., Chatsworth, CA). Viral supernatants were collected 48 h after transfection, filtered through disposable 0.45 mM cellulose acetate filters (VWR Scientific Inc. West Chester, PA, USA) and frozen in individual aliquots at À80 1C. For infection cells were plated in 60 or 100 mm tissue culture dishes (VWR) and allowed to achieve 40-50% confluence before adding viral supernatant in the presence of 8 mg ml À1 polybrene for 24 h (Sigma, St Louis, MO, USA). Cells infected with H1 lentiviral vector expressing different shRNAs were examined by fluorescence microscopy for the expression of EGFP in 48 h. Cells were then split and cultured for an additional 2-4 days after infection before being utilized for further studies.
Immunoblotting, immunohistochemistry and flow cytometry Total cell lysates were prepared and immunoblotting was performed as previously described using 50-80 mg of total protein (48). The following antibodies were used: 9E10 and C33 monoclonal antibody (mAb) for human c-Myc (SC-40, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), p53 (VP-P955, Vector Laboratories Ltd, Peterborough, UK) and p21
CIP/WAF (SC-397), H2AX-Ser139-phospho-specific antibodies (Millipore Corporation, Billerica, MA, USA), D-10 mAb against tubulin (Santa Cruz Biotechnology). Membranes were developed using enhanced chemiluminescence kit (SuperSignal West Femto Maximum Sensitivity Substrate, Pierce, Rockland, IL, USA) or using alkaline phosphatase secondary antibodies and detection/quantification of the signal was performed using ImageJ 1.38 software or STORM PhosphorImager and ImageQuant 2.0 Program as a part of ImagePro Analysis Software package. Background was calculated from an equivalent area in each lane and subtracted from the value for c-Myc in that lane. Propidium iodide staining, flow cytometry and statistical evaluation of cell cycle data were performed as previously described (Nikiforov et al., 2002; Yin et al., 2002) .
